MK-458, A SELECTIVE AND POTENT D2 RECEPTOR AGONIST IN ADVANCED PARKINSONS-DISEASE

被引：9
|
作者：
LIEBERMAN, A [1 ]
CHIN, L [1 ]
BAUMANN, G [1 ]
机构：
[1] NEW YORK INFIRM BEEKMAN DOWNTOWN MED CTR,DEPT SURG,NEW YORK,NY
来源：
CLINICAL NEUROPHARMACOLOGY | 1988年 / 11卷 / 03期
关键词：
D O I：
10.1097/00002826-198806000-00001
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：191 / 200
页数：10
相关论文
共 50 条
  • [1] RANDOMIZED STUDY OF THE PHARMACOKINETICS AND DOSE PROPORTIONALITY OF THE D2-AGONIST MK-458 (HPMC) IN PARKINSONS-DISEASE (PD)
    CUTLER, NR
    PRIOR, PL
    MCLEAN, LF
    REINES, SA
    PORRAS, AG
    HAND, EL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 49 (02) : 163 - 163
  • [2] SUSTAINED-RELEASE (+)-PHNO [MK-458 (HPMC)] IN THE TREATMENT OF PARKINSONS-DISEASE - EVIDENCE FOR TOLERANCE TO A SELECTIVE D2-RECEPTOR AGONIST ADMINISTERED AS A LONG-ACTING FORMULATION
    CEDARBAUM, JM
    CLARK, M
    TOY, LH
    GREENPARSONS, A
    MOVEMENT DISORDERS, 1990, 5 (04) : 298 - 303
  • [3] METABOLISM OF MK-458, A HIGHLY POTENT AND SELECTIVE DOPAMINE AGONIST, BY RAT-LIVER MICROSOMES
    VYAS, KP
    KARI, PH
    RAMJIT, HG
    HICHENS, M
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1988, 195 : 117 - MEDI
  • [4] PHARMACOKINETICS AND DOSE PROPORTIONALITY OF D2-AGONIST MK-458 (HPMC) IN PARKINSONISM
    CUTLER, NR
    REINES, SA
    MCLEAN, LF
    SRAMEK, JJ
    PORRAS, AG
    HAND, EL
    CLINICAL PHARMACOKINETICS, 1992, 22 (03) : 223 - 230
  • [5] SELECTIVE D-1 DOPAMINE RECEPTOR AGONIST TREATMENT OF PARKINSONS-DISEASE
    BRAUN, A
    FABBRINI, G
    MOURADIAN, MM
    SERRATI, C
    BARONE, P
    CHASE, TN
    JOURNAL OF NEURAL TRANSMISSION, 1987, 68 (1-2) : 41 - 50
  • [6] PARKINSONS-DISEASE MONOTHERAPY WITH CONTROLLED-RELEASE MK-458 (PHNO) - DOUBLE-BLIND-STUDY AND COMPARISON TO CARBIDOPA LEVODOPA
    AHLSKOG, JE
    MUENTER, MD
    BAILEY, PA
    MILLER, PM
    CLINICAL NEUROPHARMACOLOGY, 1991, 14 (03) : 214 - 227
  • [7] USE OF LISURIDE IN ADVANCED PARKINSONS-DISEASE - POTENT DOPAMINE AND SEROTONIN AGONIST
    LIEBERMAN, AN
    GOLDSTEIN, M
    NEOPHYTIDES, A
    LEIBOWITZ, M
    GOPINATHAN, G
    GOODGOLD, A
    PACT, V
    WALKER, R
    NEW YORK STATE JOURNAL OF MEDICINE, 1981, 81 (12) : 1751 - 1755
  • [8] AGONIST SUBSTITUTION IN ADVANCED PARKINSONS-DISEASE
    GOETZ, CG
    SHANNON, KM
    TANNER, CM
    CARROLL, VS
    KLAWANS, HL
    NEUROLOGY, 1989, 39 (08) : 1121 - 1122
  • [9] EFFECT OF MK-458 (HPMC) IN PARKINSONS-DISEASE PREVIOUSLY UNTREATED WITH DOPAMINERGIC DRUGS - A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY
    KOLLER, WC
    BLOCK, GA
    AHLSKOG, JE
    AHRENS, S
    CEDARBAUM, JM
    CYHAN, G
    GOETZ, CG
    LEWITT, PA
    LISS, C
    MCLEAN, L
    MOSES, H
    MUENTER, MD
    NAUSIEDA, P
    SANCHEZRAMOS, J
    REICH, S
    SINGER, C
    STELLAR, S
    WEINER, WJ
    CLINICAL NEUROPHARMACOLOGY, 1991, 14 (04) : 322 - 329
  • [10] THE USE OF PERGOLIDE, A POTENT DOPAMINE AGONIST, IN PARKINSONS-DISEASE
    LIEBERMAN, AN
    GOLDSTEIN, M
    NEOPHYTIDES, A
    LEIBOWITZ, M
    GOPINATHAN, G
    WALKER, R
    PACT, V
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1982, 32 (01) : 70 - 75
12345